future of glp-1 drugs Costs Explained: Managing Coverage Challenges GLP-1 receptor agonists | How
Description
Astrup, A
Curr Opin Endocrinol Diab Obes 2017
Read the terms of service carefully
Holman R
Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
